REN-001 is a small molecule commercialized by Reneo Pharmaceuticals, with a leading Phase III program in Mitochondrial Myopathy. According to Globaldata, it is involved in 8 clinical trials, of which 5 were completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of REN-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for REN-001 is expected to reach an annual total of $181 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
HPP-593 (REN-001) is under development for the treatment of McArdle disease (glycogen storage disorder 5), primary mitochondrial myopathy, MELAS syndrome metabolic syndromes and fatty acid oxidation disorders (FAODs) with confirmed mutations in the Carnitine palmitoyltransferase II deficiency (CPT2), Very long-chain Acyl-CoA dehydrogenase deficiency (VLCAD), Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) or Trifunctional Protein Deficiency (TFP). It is administered through the oral route. The drug candidate acts by targeting peroxisome proliferator-activated delta receptor (PPAR).
HPP-593 was also under development for the treatment of musculoskeletal disorders, dyslipidemia and type 2 diabetes.
Reneo Pharmaceuticals Overview
Reneo Pharmaceuticals, a biotechnology company that focused on developing treatments for orphan diseases. The company is headquartered in United States.
The operating loss of the company was US$39.8 million in FY2021, compared to an operating loss of US$19.6 million in FY2020. The net loss of the company was US$39.8 million in FY2021, compared to a net loss of US$19.5 million in FY2020.
For a complete picture of REN-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.